LifeArc working with the Crohn’s & Colitis Foundation to develop a prognostic test for Crohn’s disease in children
Published on 26 Jan 2021
CGT Catapult’s third annual clinical adoption workshop offers recommendations for advancing institutional readiness across the NHS to accelerate the routine adoption of cell and gene therapies
Published on 26 Jan 2021
Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration
Published on 19 Jan 2021
Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases
Published on 19 Jan 2021
Stevenage Bioscience Catalyst announces James Latham as Development and Leasing Director
Published on 12 Jan 2021
Hertfordshire LEP to part-fund state-of-the-art cell and gene therapy training centre to strengthen the sector’s skills pipeline
Published on 5 Jan 2021
Dr Sally Ann Forsyth CEO Stevenage Bioscience Catalyst Awarded OBE for Services to Business and Science
Published on 30 Dec 2020
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
Published on 22 Dec 2020
LifeArc co-leads £6 million funding in DJS Antibodies
Published on 22 Dec 2020

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Read the article
The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.
Prof. Clive Page
Chairman of Immune Regulation
CGT Catapult has won the 2020 Pharmaceutical Industry Network Group (PING) Innovation Award, hosted by VWV
Published on 15 Dec 2020
UK set to take advanced therapies and vaccine manufacturing industry to the next level: the Advanced Therapy Skills Training Network launches today – driven by industry and coordinated by the Cell and Gene Therapy Catapult
Published on 4 Dec 2020
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
Published on 1 Dec 2020
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer
Published on 1 Dec 2020
New data from Cell and Gene Therapy Catapult report shows move towards commercialisation and 48% increase in GMP manufacturing space despite COVID-19 pandemic
Published on 1 Dec 2020
Stevenage Bioscience Catalyst opens the Lab Hotel, with first residents announced as Oppilotech, Exogene and Immtune Therapies
Published on 23 Nov 2020
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
Published on 19 Nov 2020
Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
Published on 16 Nov 2020
TCR² Therapeutics Announces Partnership With Elevatebio To Expand Tc-210 Manufacturing Capacity
Published on 11 Nov 2020
Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration
Published on 11 Nov 2020
New report shows 10% of UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst
Published on 9 Nov 2020
Celebrating the achievements of the Advanced Therapies Apprenticeship Community
Published on 3 Nov 2020

Copyright © 2021 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.